Jeff Yass’s NewAmsterdam Pharma NAMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.11M Sell
86,900
-481,700
-85% -$13.3M ﹤0.01% 6137
2026
Q2
$19.3M Buy
568,600
+307,600
+118% +$10.1M ﹤0.01% 2509
2026
Q1
$8.35M Buy
261,000
+59,700
+30% +$1.94M ﹤0.01% 3387
2025
Q4
$7.06M Buy
201,300
+63,500
+46% +$2.31M ﹤0.01% 3519
2025
Q3
$3.92M Buy
137,800
+63,400
+85% +$1.52M ﹤0.01% 4507
2025
Q2
$1.35M Sell
74,400
-12,100
-14% -$221K ﹤0.01% 6693
2025
Q1
$1.77M Buy
86,500
+47,900
+124% +$1.06M ﹤0.01% 5799
2024
Q4
$992K Buy
+38,600
New +$820K ﹤0.01% 6956

Other funds holding NAMS

Jeff Yass's NAMS Position: Q3 2026 in Review

Jeff Yass reduced its NewAmsterdam Pharma (NAMS) stake by 62% in Q3 2026, selling an estimated $12.9M and leaving 286,860 shares worth $6.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3890.

Jeff Yass first reported a position in NAMS in Q4 2024 and has held it in 8 quarters since. The position peaked at $25.6M in Q2 2026. 183 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

  • Jeff Yass held 286,860 shares of NewAmsterdam Pharma worth $6.98M as of Q3 2026.
  • Jeff Yass sold 467,467 NewAmsterdam Pharma shares in Q3 2026, an estimated $12.9M.
  • NewAmsterdam Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #3890 holding.
  • Jeff Yass first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 8 quarters since.
  • Jeff Yass's NewAmsterdam Pharma position peaked at $25.6M in Q2 2026.
  • 183 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.